EVMN
Evommune, Inc.
NYSE · Healthcare · Biotechnology · US
$6.03
+1.52%Jun 30, 2026, 16:16 UTC
Evommune's phase IIb clinical trial for EVO756 in chronic spontaneous urticaria failed to meet its primary endpoint.
Source:
NYSE · Healthcare · Biotechnology · US
Jun 30, 2026, 16:16 UTC